Clinical trial · no report yet · Phase 3
AEGEAN
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
- NCT03800134 ↗
- Active not recruiting
- AstraZeneca
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab; Placebo; Carboplatin; Cisplatin; Pemetrexed; Paclitaxel; Gemcitabine; Surgery
- Arms
- Arm 1: Durvalumab with platinum-based chemotherapy · Experimental
- Arm 2: Placebo with platinum-based chemotherapy · Placebo comparator
- Enrollment
- 825
- Primary outcomes
- Pathological Complete Response (pCR) in modified intent-to-treat (mITT) population
- Event-Free Survival (EFS) in modified intent to treat (mITT) population
- Sponsor
- AstraZeneca
- Start
- Dec 6, 2018
- Primary completion
- Nov 10, 2022
- Results posted
- No
- Registry record
- NCT03800134 · updated Jun 11, 2025
Publications
linked from the registry- Mitsudomi T, Heymach JV, Horio Y, Tanaka F, Tanaka H, Kuyama S, Okada M, Toyooka S, Watanabe Y, Reck M, Harpole D, Taube JM, Olivo Y, Xiong H, Fouad TM, Chen A, Akamatsu H. Perioperative Durvalumab for Resectable NSCLC: Updated Outcomes for Japanese Patients in AEGEAN. Cancer Sci. 2026 Sep 27:10.1111/cas.70541. doi: 10.1111/cas.70541. Online ahead of print. PubMed 42802029
- Mitsudomi T, Heymach JV, Reck M, Taube JM, Gao S, Horio Y, You J, Li G, Van Luong D, Saeteng S, Tanaka F, Watzka SB, Urban L, Szalai Z, Akamatsu H, Kang JH, Orlandi FJ, Mukhametshina GZ, Pircher A, Teixeira CHA, Aperghis M, Doherty GJ, Doake R, Fouad TM, Harpole D. Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC. J Thorac Oncol. 2025 Nov;20(11):1639-1654. doi: 10.1016/j.jtho.2025.06.015. Epub 2025 Jun 20. PubMed 40545237
- Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, Kuroda H, Ostoros G, Tran TV, You J, Lee KY, Antonuzzo L, Papai-Szekely Z, Akamatsu H, Biswas B, Spira A, Crawford J, Le HT, Aperghis M, Doherty GJ, Mann H, Fouad TM, Reck M; AEGEAN Investigators. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023 Nov 2;389(18):1672-1684. doi: 10.1056/NEJMoa2304875. Epub 2023 Oct 23. PubMed 37870974